European Heart Journal Advance Access originally published online on November 7, 2006
European Heart Journal 2007 28(3):292-298; doi:10.1093/eurheartj/ehl361
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Association between plasma adiponectin levels and unstable coronary syndromes
1 Division of Cardiovascular Diseases, Mayo Clinic, 1216 Second Street SW, Rochester, MN 55902, USA
2 Division of Biostatistics, Mayo Clinic, Rochester, MN, USA
Received 5 April 2006; revised 11 October 2006; accepted 19 October 2006; online publish-ahead-of-print 7 November 2006.
* Corresponding author. Tel: +1 507 2551144; fax: +1 507 2557070. E-mail address: wolk.robert{at}mayo.edu
See page 274 for the editorial comment on this article (doi:10.1093/eurheartj/ehl454)
Aims Obesity is a risk factor for an acute coronary syndrome (ACS). The association between elevated body mass index (BMI) and ACS is independent of most traditional risk factors, suggesting a possible contribution of other body fat-related mediators. This study evaluated the association between adiponectin and ACS.
Methods and results Four hundred and ninety-nine patients undergoing coronary angiography were divided into a subgroup without (n = 331) and with ACS (n = 168). In multiple regression analysis, higher adiponectin levels were independently associated with a lower risk of ACS [odds ratio (OR) = 0.61; 95% CIs: 0.46–0.81; P < 0.001]. In contrast, a higher BMI, a history of myocardial infarction, C-reactive protein, and angiographic coronary artery disease severity were all associated with a higher risk. The greatest increase in risk for ACS was seen at adiponectin levels 
5.5 µg/mL.
Conclusion Higher plasma adiponectin levels are independently associated with a lower risk of ACS.
Key Words: Adipokines • Adiponectin • C-reactive protein • Acute coronary syndrome • Atherosclerosis • Angiography
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Adiponectin and risk of acute coronary syndromes: defining the obesity phenotype
- Tobias Pischon and Eric B. Rimm
EHJ 2007 28: 274-275.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  G. R. Hajer, T. W. van Haeften, and F. L.J. Visseren Adipose tissue dysfunction in obesity, diabetes, and vascular diseases Eur. Heart J., September 5, 2008; (2008) ehn387v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Empana Adiponectin isoforms and cardiovascular disease: the epidemiological evidence has just begun Eur. Heart J., May 2, 2008; 29(10): 1221 - 1223. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1489 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Giugliano and E. Braunwald The Year in Non ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1386 - 1395. [Full Text] [PDF]
|
|
|
|
|
|
T. Pischon and E. B. Rimm Adiponectin and risk of acute coronary syndromes: defining the obesity phenotype Eur. Heart J., February 1, 2007; 28(3): 274 - 275. [Full Text] [PDF]
|
|